Chongqing Lummy Pharmaceutical Co.Ltd(300006)
Independent directors’ opinions on the 22nd Meeting of the 5th board of directors
Prior approval opinions on relevant matters
In accordance with the relevant provisions of laws, regulations and rules such as the rules for independent directors of listed companies, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM, the articles of association of Chongqing Lummy Pharmaceutical Co.Ltd(300006) (hereinafter referred to as the “company”), the working system of independent directors and other laws, regulations and rules of China Securities Regulatory Commission, as independent directors of the company, based on objective and independent judgment, The company reviewed and reviewed the proposal on renewing the appointment of accounting firms considered at the 22nd Meeting of the 5th board of directors in advance, and issued the following prior approval opinions:
Sichuan Huaxin (Group) Certified Public Accountants (special general partnership) (hereinafter referred to as “Sichuan Huaxin”) has the securities practice qualification approved by the CSRC. The signing certified public accountants and project leaders have many years of experience and ability to provide audit services for listed companies. In the process of cooperation with the company, they can adhere to the principle of independent audit, issue various professional reports for the company on time, and the contents of the reports are objective and fair. Sichuan Huaxin has sufficient independence, professional competence, investor protection ability and good integrity. We agree that the company will continue to appoint Sichuan Huaxin as the accounting firm of the company in 2022. We agree that the company will submit the matter to the board of directors for deliberation.
Independent directors: Chen Xujiang, Chen Geng, Li Changbi March 24, 2022
